Apr 7 |
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
|
Mar 29 |
Those who invested in Alnylam Pharmaceuticals (NASDAQ:ALNY) five years ago are up 63%
|
Mar 20 |
Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
|
Mar 17 |
30 Biggest Biotechnology Companies in the World
|
Mar 13 |
Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease
|
Mar 10 |
Is Alnylam's HELIOS-B Delay A Red Flag?
|
Mar 6 |
Alnylam (ALNY), Roche's Blood Pressure Drug Meets Study Goal
|
Mar 5 |
Alnylam, Roche mark second Phase 2 win for blood pressure therapy
|
Mar 5 |
Roche, Alnylam say blood pressure drug succeeds in mid-stage trial
|
Mar 5 |
Alnylam, Roche blood pressure drug scores in second mid-stage trial
|